Leerink Partners analyst Puneet Souda has maintained their bullish stance on NTRA stock, giving a Buy rating on August 9.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Puneet Souda’s rating is based on the promising results from Natera’s IMvigor011 trial, which demonstrated significant improvements in disease-free survival (DFS) and overall survival (OS) for patients treated with atezolizumab when stratified with Signatera. This trial adds to the growing body of evidence supporting Signatera’s clinical utility, particularly in muscle invasive bladder cancer (MIBC), and follows earlier positive results in colorectal cancer. The anticipation of launching an FDA-approved version of Signatera as a companion diagnostic (CDx) for atezolizumab further strengthens its market position.
Puneet Souda also highlights the potential impact of updated NCCN guidelines, which could significantly boost the adoption of Signatera in the community oncology setting, where the majority of cancer patients are treated. The expected increase in minimal residual disease (MRD) utilization, as indicated by surveys of oncologists, positions Natera to capture substantial market growth. The consistent increase in Signatera’s unit volumes and the potential for reimbursement from commercial payors further support the Buy rating.
Souda covers the Healthcare sector, focusing on stocks such as Exact Sciences, Quanterix, and Agilent. According to TipRanks, Souda has an average return of -7.1% and a 34.88% success rate on recommended stocks.
In another report released on August 9, TR | OpenAI – 4o also upgraded the stock to a Buy with a $167.00 price target.